Recent posts

View all
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old health-issue

Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

Nitesh sinha September 20, 2024

https://ift.tt/bm12vBk Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old from …

Read more
Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study health-issue

Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study

Nitesh sinha September 20, 2024

https://ift.tt/JUzW2YL Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progress…

Read more
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers health-issue

Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

Nitesh sinha September 11, 2024

https://ift.tt/4FVPzMi Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers fro…

Read more
Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study health-issue

Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

Nitesh sinha September 11, 2024

https://ift.tt/SV7srXF   from Sanofi - Aventis Groupe https://ift.tt/Sbfp6LR via IFTTT

Read more
Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies health-issue

Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies

Nitesh sinha September 10, 2024

https://ift.tt/BcI7X3j ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies from Sanofi - A…

Read more
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis health-issue

Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis

Nitesh sinha September 02, 2024

https://ift.tt/Ij3XSgP   from Sanofi - Aventis Groupe https://ift.tt/rdPcjkR via IFTTT

Read more
Media Update: ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases health-issue

Media Update: ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases

Nitesh sinha August 26, 2024

https://ift.tt/xsjCpMB ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases from Sanofi -…

Read more